Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 07, 2020

SELL
$64.5 - $97.79 $33,153 - $50,264
-514 Closed
0 $0
Q4 2019

Feb 03, 2020

SELL
$72.13 - $90.25 $577 - $722
-8 Reduced 1.53%
514 $45,000
Q3 2019

Nov 07, 2019

BUY
$62.98 - $75.72 $566 - $681
9 Added 1.75%
522 $39,000
Q2 2019

Jul 31, 2019

SELL
$65.7 - $83.98 $234,154 - $299,304
-3,564 Reduced 87.42%
513 $0
Q1 2019

Apr 08, 2019

BUY
$77.14 - $90.79 $26,459 - $31,140
343 Added 9.19%
4,077 $327,000
Q4 2018

Jan 25, 2019

SELL
$77.85 - $96.01 $88,048 - $108,587
-1,131 Reduced 23.25%
3,734 $346,000
Q1 2018

Nov 14, 2018

SELL
$92.01 - $123.21 $31,283 - $41,891
-340 Reduced 6.53%
4,865 $461,000
Q4 2017

Nov 13, 2018

SELL
$89.56 - $98.21 $895 - $982
-10 Reduced 0.19%
5,205 $502,000
Q3 2017

Dec 06, 2018

BUY
$69.85 - $89.22 $79,908 - $102,067
1,144 Added 28.1%
5,215 $465,000
Q2 2017

Dec 06, 2018

BUY
N/A
3,250 Added 395.86%
4,071 $295,000
Q4 2016

Dec 05, 2018

BUY
N/A
821
821 $51,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Bell Rock Capital LLC Portfolio

Follow Bell Rock Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bell Rock Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bell Rock Capital LLC with notifications on news.